Eli Lilly (LLY) Shareholder's Equity (2009 - 2026)

Eli Lilly (LLY) Shareholder's Equity (2009 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Shareholder's Equity (Qtr)
1 Gsk 93,699,046.73 Bn 93,699,041.77 Bn 7.76 Bn -
2 Eli Lilly 1,012.06 Bn 1,006.77 Bn 16.22 Bn 31.20 Bn
3 Johnson & Johnson 560.67 Bn 538.62 Bn 15.96 Bn 81.19 Bn
4 AbbVie 402.20 Bn 392.85 Bn 10.78 Bn -6.66 Bn
5 Merck 298.59 Bn 292.94 Bn 12.09 Bn 45.88 Bn
6 Amgen 188.77 Bn 176.74 Bn 5.87 Bn 9.19 Bn
7 Gilead Sciences 160.22 Bn 152.49 Bn 5.52 Bn 23.52 Bn
8 Pfizer 148.19 Bn 135.42 Bn -1.21 Bn 90.10 Bn
9 Bristol Myers Squibb 116.72 Bn 106.26 Bn 8.07 Bn 20.07 Bn
10 Novartis Ag 109.78 Bn 109.09 Bn - -

Historic Data

Download Data
DateValue
Mar 31, 2026 31.20 Bn
Dec 31, 2025 26.54 Bn
Sep 30, 2025 23.85 Bn
Jun 30, 2025 -55.40 Mn
Mar 31, 2025 -2.18 Bn
Dec 31, 2024 246.00 Mn
Sep 30, 2024 -1.88 Bn
Jun 30, 2024 73.50 Mn
Mar 31, 2024 -4.30 Bn
Dec 31, 2023 -3.01 Bn
Sep 30, 2023 -45.00 Mn
Jun 30, 2023 -1.89 Bn
Mar 31, 2023 -3.78 Bn
Dec 31, 2022 91.00 Mn
Sep 30, 2022 -4.30 Bn
Jun 30, 2022 -4.29 Bn
Mar 31, 2022 -4.23 Bn
Dec 31, 2021 -4.34 Bn
Sep 30, 2021 -4.47 Bn
Jun 30, 2021 8.53 Bn